Example: Heart Attack

Search clinical trials for: Rituximab

Total 1644 results

NCT04609046

Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
NCT04666038

Recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
NCT03684980

Recruiting

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A

Conditions: Central Nervous System Lymphoma
NCT03740529

Recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
NCT04136756

Recruiting

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
NCT02073097

Recruiting

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
NCT01059786

Recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Conditions: Hairy Cell Leukemia
NCT04933617

Not yet recruiting

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
NCT00001337

Active, not recruiting

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
NCT04759586

Suspended

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Conditions: Primary Mediastinal (Thymic) Large B-Cell Lymphoma
NCT03834688

Recruiting

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Conditions: Mantle Cell Lymphoma
NCT01419561

Recruiting

History of the KSHV Inflammatory Cytokine Syndrome (KICS)

Conditions: KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
NCT04840602

Not yet recruiting

Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
NCT03036904

Active, not recruiting

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
NCT02471911

Active, not recruiting

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Conditions: Diffuse Large B-Cell Lymphoma
NCT02169219

Completed

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
NCT00977977

Recruiting

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Conditions: Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
NCT04938297

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Conditions: Central Nervous System Lymphoma
NCT03789240

Recruiting

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Conditions: Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
NCT04436107

Recruiting

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04679012

Not yet recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Conditions: Richter Syndrome, Chronic Lymphocytic Leukemia
NCT01030900

Active, not recruiting

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Conditions: Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
NCT03984448

Recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
NCT02953509

Recruiting

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Conditions: Non Hodgkin Lymphoma
NCT00602459

Active, not recruiting

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia